Welcome to our dedicated page for Scholar Rock Holding SEC filings (Ticker: SRRK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Scholar Rock Holding Corporation filings document the public-company record of a Nasdaq-listed biopharmaceutical issuer focused on apitegromab, spinal muscular atrophy, and myostatin biology programs. Current reports on Form 8-K cover operating and financial results, Regulation FD business updates, apitegromab regulatory disclosures, preliminary cash updates, and amendments correcting furnished earnings materials.
The company’s SEC record also includes proxy materials for director elections, auditor ratification, and advisory executive-compensation votes. Capital-structure disclosures identify SRRK common stock listed on the Nasdaq Global Select Market and include shelf registration and at-the-market offering materials for common stock sales.
Jeffrey S. Flier, Director of Scholar Rock Holding Corp (SRRK), executed several transactions on June 23, 2025, as part of a pre-planned Rule 10b5-1 trading plan established on February 27, 2025:
- Exercised 20,316 stock options at $21.62 per share
- Sold 17,550 shares at weighted average price of $32.16
- Sold 2,766 shares at weighted average price of $32.74
- Sold 11,136 shares at weighted average price of $33.21 (held in family trust)
Following these transactions, Flier directly owns 24,070 shares (including 16,438 common shares and 7,632 RSUs) and indirectly owns 11,136 shares through The Jeffrey S. Flier Family Trust - 2014. The exercised stock option has no remaining unvested shares. These transactions represent a significant reduction in Flier's direct holdings, suggesting potential portfolio rebalancing or profit-taking with the stock trading above $32.